Differences in Early-Onset vs. Average-Onset Cholangiocarcinoma: Therapeutic Insights Gastrointestinal 7 Mins Read66 Thejus Jayakrishnan, MD: [00:00:00] Those of you who have listened to the keynote address today by Dr. Ng from Dana…
Cholangiocarcinoma: Ipilimumab and Nivolumab Combo Other 3 Mins Read1 Cholangiocarcinoma: Ipilimumab and Nivolumab Combo  MOASC Poster Session 2022 (Cholangiocarcinoma Ipilimumab Nivolumab) Hello, my name is Dalia Kaakour (clinical…
